* Q2 adj. EBITDA 25% below consensus on 12% sales miss * FY guidance cut; cons '25e EBITDA to come d...
Redeye comments on Gentoo Media’s Q2-results which were lower than expected and the company has trim...
Solwers reported its results for Q2 with sales of EUR 21.
Redeye views last Friday’s large block transaction in Physitrack shares as a clear positive for the ...
Redeye provides an update following Neola Medical’s Q2 2025 report.
Redeye comments on Episurf’s rights issue of Units, which was oversubscribed to approximately 162.
Redeye comments on Elicera reporting data from cohort 2 in the ongoing CARMA study.
Redeye provides its preview of Integrum’s Q1 2025 report, due on Monday, September 1.
Redeye comments on Active Biotech's second quarter report.
Redeye reviews the case for IDL Diagnostics, and while we down our medium-term sales forecasts, we r...
Egetis has rapidly transferred all but one German patient, supporting the launch and indicating posi...
Crunchfish’s new go-to-market strategy for offline payments, splitting the solution into terminals f...
Redeye has updated its estimates and valuation for Sleep Cycle following the Q2 2025 report, which w...
Redeye provides an update following CLS’s Q2 2025 report.
Redeye updates its estimates and valuation following Navigo’s Q2 2025 report.
Redeye argues that AVTECH has delivered another strong report with sales growth of 37% y/y, which wa...
* Net acquistions in H2'25 * Buy-backs supportive for the share * 2025e P/CEPS 11x vs.
* A quarter centred on preparations * Orviglance FDA submission around the corner * Fair value range...
* Weaker Q2 due to natural quarterly variations * Cut '25e-'27e EBIT by 12-13% * Demand intact, rebo...
* Gross margin at 45% (40%) * SaaS supports margins and outlook * Trading at ~11-9x EV/EBITA for '26...
